CoChat

Treatment of colitis with a commensal gut bacterium engineered to secrete human tgf-β1 under the control of dietary xylan

Hamady, Zaed Z.R., Scott, Nigel, Farrar, Mark D., Wadhwa, Meenu, Dilger, Paula, Whitehead, Terence R., Thorpe, Robin, Holland, Keith T., Lodge, Peter J.A., Carding, Simon R. · 2011 · Inflammatory Bowel Diseases
Cited by 110

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

BACKGROUND: While cytokine therapy and the use of immunosuppressive cytokines such as transforming growth factor-β (TGF-β) offer great potential for the treatment of inflammatory bowel disease (IBD), issues concerning formulation, stability in vivo, delivery to target tissues, and potential toxicity need to be addressed. In consideration of these problems we engineered the human commensal bacterium Bacteroides ovatus for the controlled in situ delivery of TGF-β(1) and treatment of colitis. METHODS: Sequence encoding the human tgf-β1 gene was cloned downstream of the xylanase promoter in the xylan operon of B. ovatus by homologous recombination. Resulting recombinants (BO-TGF) were tested for TGF-β production in the presence and absence of polysaccharide xylan in vitro and in vivo, and used to treat experimental murine colitis. Clinical and pathological scores were used to assess the effectiveness of therapy. Colonic inflammatory markers including inflammatory cytokine expression were assessed by colorimetric assay and real-time polymerase chain reaction (PCR). RESULTS: BO-TGF secreted high levels of biologically active dimeric TGF-β in vitro and in vivo in a xylan-controlled manner. Administration of xylan in drinking water to BO-TGF-treated mice resulted in a significant clinical improvement of colitis, accelerating healing of damaged colonic epithelium, reducing inflammatory cell infiltration, reducing expression of proinflammatory cytokines, and promoting production of mucin-rich goblet cells in colonic crypts. These beneficial effects are comparable and in most cases superior to that achieved by conventional steroid therapy. CONCLUSIONS: This novel drug delivery system has potential for the targeted and controlled delivery of TGF-β(1) and other immunotherapeutic agents for the long-term management of various bowel disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ibd.21565

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • A Phase I Trial With Transgenic Bacteria Expressing Interleukin-10 in Crohn’s Disease

    Braat, H., Rottiers, P., Hommes, D. W., Huyghebaert, N., Remaut, E., Remon, J., van Deventer, S. J. H., Neirynck, S., Peppelenbosch, M. P., & Steidler, L. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.03.028 · Cited by 786 · cited 4×

    “One of the most commonly exploited bacteria for drug delivery is Lactococcus lactis, a Gram-positive bacteria used extensively in the dairy industry and the first genetically modified organism to be used alive for the treatment of IBD.21 Strains of L. lactis secreting the antiinflammatory cytokine IL-10 were shown to…”
    BackgroundInfluential
  • Role of cytokines in inflammatory bowel disease

    Sanchez-Muñoz, F., Dominguez-Lopez, A., & Yamamoto-Furusho, J. K. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.4280 · Cited by 699 · cited 1×

    “, interleukin [IL]-10 and transforming growth factor beta [TGF-b]) being linked to the development of IBD in both experimental models and patients.(3) An immunosuppressive cytokine that is central to maintaining intestinal homeostasis is TGF-b1.”
    Background

Cited by

See all 110

Metadata

Authors
Hamady, Z. Z. R., Scott, N., Farrar, M. D., Wadhwa, M., Dilger, P., Whitehead, T. R., Thorpe, R., Holland, K. T., Lodge, P. J. A., & Carding, S. R.
Venue
Inflammatory Bowel Diseases
Published
2011-09
Volume
17
Issue
9
Pages
1925-1935
ISSN
1078-0998 (ISSN-L)
OpenAlex
W2155244646
Cited by
110
References
2
FWCI
2.01
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.